You are here
Oral Solution of Memantine for Moderate to Severe Alzheimer’s Disease Now Available
The oral solution of Namenda is equivalent on a milligram per milligram basis to the Namenda tablets and is administered in the same manner. Namenda oral solution is available in a 2 mg/ml concentration, 360 ml (12 oz) bottle.
Namenda (memantine HCl) is the first in a class of medications with a unique mechanism of action that focuses on the glutamate pathway, a target for the treatment of Alzheimer’s disease. Indicated for the treatment of moderate to severe Alzheimer's disease, the FDA approved Namenda (October 2003) based on three studies of Namenda used alone or in combination with another Alzheimer’s disease drug.
Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
Source: Forest Laboratories, Inc.